Integrated Filing — IndAS



General information about company
Scrip Code 531349
NSE Symbol PANACEABIO
MSEI Symbol NOTLISTED
ISIN INE922B01023
Name of company PANACEA BIOTEC LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 30-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 24-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Vaccine
Start date and time of board meeting 30-May-2025   14:30:00
End date and time of board meeting 30-May-2025   17:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public No
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-14
Indicate Company website link for updated RPT policy of the Company www.panaceabiotec.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There is no default on loans.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 679000000 3098500000
Other income 60900000 166200000
Total income 739900000 3264700000
2 Expenses
(a) Cost of materials consumed 593700000 1240100000
(b) Purchases of stock-in-trade 17500000 17500000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -341000000 -230600000
(d) Employee benefit expense 272600000 970200000
(e) Finance costs 46400000 154600000
(f) Depreciation, depletion and amortisation expense 49100000 202900000
(f) Other Expenses
1 other expenses 321900000 1170600000
Total other expenses 321900000 1170600000
Total expenses 960200000 3525300000
3 Total profit before exceptional items and tax -220300000 -260600000
4 Exceptional items 0 0
5 Total profit before tax -220300000 -260600000
6 Tax expense
7 Current tax 0 0
8 Deferred tax -96400000 -108300000
9 Total tax expenses -96400000 -108300000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations -123900000 -152300000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period -123900000 -152300000
17 Other comprehensive income net of taxes 1000000 500000
18 Total Comprehensive Income for the period -122900000 -151800000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 61300000 61300000
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 3078400000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -2.02 -2.49
Diluted earnings (loss) per share from continuing operations -2.02 -2.49
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -2.02 -2.49
Diluted earnings (loss) per share from continuing and discontinued operations -2.02 -2.49
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 3475000000
Capital work-in-progress 874000000
Investment property 682300000
Goodwill 0
Other intangible assets 5700000
Intangible assets under development 316400000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 2700000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 23000000
Total non-current financial assets 25700000
Deferred tax assets (net)
Other non-current assets 378300000
Total non-current assets 5757400000
2 Current assets
Inventories 1521000000
Current financial asset
Current investments 0
Trade receivables, current 208500000
Cash and cash equivalents 385000000
Bank balance other than cash and cash equivalents 236600000
Loans, current 17700000
Other current financial assets 164000000
Total current financial assets 1011800000
Current tax assets (net) 0
Other current assets 404500000
Total current assets 2937300000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 8694700000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 61300000
Other equity 3078400000
Total equity attributable to owners of parent 3139700000
Non controlling interest
Total equity 3139700000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1605100000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 96500000
Total non-current financial liabilities 1701600000
Provisions, non-current 199500000
Deferred tax liabilities (net) 139800000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 2040900000
Current liabilities
Current financial liabilities
Borrowings, current 679400000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 95500000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1552800000
Total Trade payable 1648300000
Other current financial liabilities 92400000
Total current financial liabilities 2420100000
Other current liabilities 784700000
Provisions, current 309300000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 3514100000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 5555000000
Total equity and liabilites 8694700000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss 1300000 700000
Total Amount of items that will not be reclassified to profit and loss 1300000 700000
2 Income tax relating to items that will not be reclassified to profit or loss 300000 200000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 1000000 500000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax -260600000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 154600000
Adjustments for decrease (increase) in inventories -441700000
Adjustments for decrease (increase) in trade receivables, current -100400000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -85100000
Adjustments for decrease (increase) in other non-current assets 114500000
Adjustments for other financial assets, non-current -800000
Adjustments for other financial assets, current 9400000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 487300000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -7300000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 202900000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 10300000
Adjustments for provisions, non-current 41300000
Adjustments for other financial liabilities, current -16100000
Adjustments for other financial liabilities, non-current 300000
Adjustments for unrealised foreign exchange losses gains 12700000
Adjustments for dividend income 0
Adjustments for interest income 94900000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 56700000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 343700000
Net cash flows from (used in) operations 83100000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 11100000
Other inflows (outflows) of cash -32600000
Net cash flows from (used in) operating activities 39400000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 1400000
Purchase of property, plant and equipment 529700000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 28100000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -105800000
Net cash flows from (used in) investing activities -606000000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 1072700000
Repayments of borrowings 145000000
Payments of lease liabilities 0
Dividends paid 0
Interest paid 27000000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities 900700000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 334100000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 334100000
Cash and cash equivalents cash flow statement at beginning of period 50900000
Cash and cash equivalents cash flow statement at end of period 385000000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s Suresh Surana & Associates Yes 31-Mar-2028


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Panacea Biotec Limited Adveta Power Private Limited Joint Venture Any other transaction Rental Income As approved by Board 51000 610000 670000
2 Panacea Biotec Limited Adveta Power Private Limited Joint Venture Investment As approved by Board 0 900000 900000
3 Panacea Biotec Pharma Limited Adveta Power Private Limited Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Any other transaction Interest accrued on loans given As approved by Board 24000 22000 44000
4 Panacea Biotec Pharma Limited Adveta Power Private Limited Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Loan As approved by Board 0 545000 545000
5 Panacea Biotec Pharma Limited Panacea Biotec Germany Gmbh Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Sale of goods or services As approved by Board 12509000 0 0
6 Panacea Biotec Limited Dr. Rajesh Jain Chairman and Managing Director Interest paid As approved by Board 6732000 0 0
7 Panacea Biotec Limited Dr. Rajesh Jain Chairman and Managing Director Loan As approved by Board 0 150000000 150000000
8 Panacea Biotec Limited Dr. Rajesh Jain Chairman and Managing Director Remuneration As approved by Nomination and Remuneration Committee, Board and Shareholders 5007000 0 0
9 Panacea Biotec Limited Meyten Realtech Private Limited Wholly owned subsidiary Any other transaction Rental Income As approved by Board 9000 4000 14000
10 Panacea Biotec Limited Meyten Realtech Private Limited Wholly owned subsidiary Any other transaction Rent paid As approved by Board 2766000 2189000 3478000
11 Panacea Biotec Limited Meyten Realtech Private Limited Wholly owned subsidiary Investment As approved by Board 0 100000 100000
12 Panacea Biotec Limited Rees Investment Limited Wholly owned subsidiary (Liquidated on May 23, 2019) Loan As approved by Board 0 585159000 585159000
13 Panacea Biotec Limited Rees Investment Limited Wholly owned subsidiary (Liquidated on May 23, 2019) Any other transaction Provision made on loan given As approved by Board 0 585189000 585159000
14 Panacea Biotec Limited Mr. Ankesh Jain Whole - time Director Remuneration As approved by Nomination and Remuneration Committee, Board and Shareholders 60000 0 0
15 Panacea Biotec Limited Mr. Ashwani Jain Chief Operating Officer Remuneration As approved by Board 1511000 0 0
16 Panacea Biotec Limited Mr. Devender Gupta CFO and Head Information Technology Remuneration As approved by Nomination and Remuneration Committee, Board and Shareholders 7060000 0 0
17 Panacea Biotec Limited Mr. Harshet Jain Member of Promoter Group Remuneration As approved by Board 1364000 0 0
18 Panacea Biotec Limited Mr. Mukul Gupta Independent Director Remuneration As approved by Board 200000 0 0
19 Panacea Biotec Limited Mr. Narotam Kumar Juneja Non-Executive Non-Independent Director Remuneration As approved by Board 150000 0 0
20 Panacea Biotec Pharma Limited Mr. Narotam Kumar Juneja Whole-time Director Remuneration As approved by Board 1028000 0 0
21 Panacea Biotec Pharma Limited Mrs. Manjula Upadhyay Independent Director Remuneration As approved by Board 170000 0 0
22 Panacea Biotec Pharma Limited Mr. Taric Jain Sr. Software Engineer Remuneration As approved by Board 1082000 0 0
23 Panacea Biotec Pharma Limited Mr. Ankesh Jain Whole-time Director Remuneration As approved by Board 1423000 0 0
24 Panacea Biotec Limited Mrs. Ambika sharma Independent Director Remuneration As approved by Board 170000 0 0
25 Panacea Biotec Limited Mrs. Manjula Upadhyay Independent Director Remuneration As approved by Board 150000 0 0
26 Panacea Biotec Limited Mr. Ankesh Jain Whole - time Director Remuneration As approved by Board 60000 0 0
27 Panacea Biotec Limited Mr. Sandeep Jain Joint Managing Director Remuneration As approved by Nomination and Remuneration Committee, Board and Shareholders 4564000 0 0
28 Panacea Biotec Limited Mr. Tanish Jain Assistant Manager Remuneration As approved by Board 518000 0 0
29 Panacea Biotec Limited Mr. Vinod Goel Group CFO and Head Legal & Company Secretary Remuneration As approved by Nomination and Remuneration Committee and Board 3849000 0 0
30 Panacea Biotec Limited CA Rajesh Jain Non-Executive Non-Independent Director Remuneration As approved by Board 155000 0 0
31 Panacea Biotec Pharma Limited CA Rajesh Jain Non-Executive Non-Independent Director Remuneration As approved by Board 145000 0 0
32 Panacea Biotec Limited Dr. Sanjay Trehan (w.e.f. 14.02.2025) Whole-time Director Any other transaction Consultancy Charges As approved by Nomination and Remuneration Committee, Board and Shareholders 268000 0 0
33 Panacea Biotec Pharma Limited Dr. Sanjay Trehan (w.e.f. 13.02.2025) Whole-time Director Any other transaction Consultancy Charges As approved by Nomination and Remuneration Committee, Board and Shareholders 192000 0 0
34 Panacea Biotec Limited MR Lex Corp LLP Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Purchase of goods or services As approved by Board 146000 389000 163000
35 Panacea Biotec Limited Neophar Alipro Limited Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Any other transaction Rental income As approved by Board 90000 0 0
36 Panacea Biotec Limited Panacea Biotec (International) S.A., Switzerland Wholly owned subsidiary Any other transaction Allowance for doubtful loan As approved by Board 0 123485000 123485000
37 Panacea Biotec Limited Panacea Biotec (International) S.A., Switzerland Wholly owned subsidiary Loan As approved by Board 0 123485000 123485000
38 Panacea Biotec Limited Panacea Biotec (International) S.A., Switzerland Wholly owned subsidiary Investment As approved by Board 0 34361000 34361000
39 Panacea Biotec Limited Panacea Biotec (International) S.A., Switzerland Wholly owned subsidiary Any other transaction Provision for impairment of Investment As approved by Board 0 34361000 34361000
40 Panacea Biotec Limited Panacea Biotec (International) S.A., Switzerland Wholly owned subsidiary Interest received As approved by Board 7828000 7692000 15520000
41 Panacea Biotec Limited Panacea Biotec (International) S.A., Switzerland Wholly owned subsidiary Any other transaction Provision for impairment of Investment As approved by Board 7828000 7692000 15520000
42 Panacea Biotec Limited Panacea Biotec Germany Gmbh Fellow subsidiary Any other transaction Allowance for doubtful loan As approved by Board 0 407669000 407669000
43 Panacea Biotec Limited Panacea Biotec Germany Gmbh Fellow subsidiary Loan As approved by Board 0 407669000 407669000
44 Panacea Biotec Limited Panacea Biotec Germany Gmbh Fellow subsidiary Interest received As approved by Board 25842000 25390000 51232000
45 Panacea Biotec Limited Panacea Biotec Germany Gmbh Fellow subsidiary Any other transaction Provision for impairment of Interest Income As approved by Board 25842000 25390000 51232000
46 Panacea Biotec Limited Panacea Biotec Pharma Limited Wholly owned subsidiary Any other transaction Trade Payable As approved by Board 139155000 142553000 3398000
47 Panacea Biotec Limited Panacea Biotec Germany Gmbh Fellow subsidiary Any other transaction Trade Receivable As approved by Board 10000 1166000 1156000
48 Panacea Biotec Limited Panacea Biotec Germany Gmbh Fellow subsidiary Any other transaction Trade Payable As approved by Board 187000 21977000 21791000
49 Panacea Biotec Limited Panacea Biotec Pharma Limited Wholly owned subsidiary Sale of goods or services As approved by Board 84000 0 0
50 Panacea Biotec Limited Panacea Biotec Pharma Limited Wholly owned subsidiary Any other transaction Rental Income As approved by Board 13968000 0 0
51 Panacea Biotec Limited Panacea Biotec Pharma Limited Wholly owned subsidiary Any other transaction Interest Expense and Interest accrued on borrowing As approved by Board 67922000 48310000 109440000
52 Panacea Biotec Limited Panacea Biotec Pharma Limited Wholly owned subsidiary Purchase of goods or services As approved by Board 378000 0 0
53 Panacea Biotec Limited Panacea Biotec Pharma Limited Wholly owned subsidiary Any other transaction Transfer of accrued retirement benefits upon transfer of employees As approved by Board 3398000 0 0
54 Panacea Biotec Limited Panacea Biotec Pharma Limited Wholly owned subsidiary Any other transaction Reimbursement of expenses As approved by Board 14258000 0 0
55 Panacea Biotec Limited Panacea Biotec Pharma Limited Wholly owned subsidiary Any other transaction Recovery of expenses As approved by Board 108000 0 0
56 Panacea Biotec Limited Panacea Biotec Pharma Limited Wholly owned subsidiary Investment As approved by Board 0 1000000 1000000
57 Panacea Biotec Limited Panacea Biotec Pharma Limited Wholly owned subsidiary Any other transaction Borrowings As approved by Board 677218000 1385233000 2062452000
58 Panacea Biotec Limited Panacea Biotec Pharma Limited Wholly owned subsidiary Any other transaction Rent paid As approved by Board 55000 142553000 2061000
59 Panacea Biotec Limited Panacea Biotec Germany Gmbh Wholly owned subsidiary Any other transaction Trade Receivable As approved by Board 12509000 1166000 2346000
60 Panacea Biotec Limited PanEra Biotec Private Limited Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Any other transaction Rental Income As approved by Board 81000 317000 413000
61 Panacea Biotec Limited PanEra Biotec Private Limited Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Investment As approved by Board 0 4198000 4198000
62 Panacea Biotec Limited PanEra Biotec Private Limited Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Any other transaction Provision for impairment of Investment As approved by Board 0 4198000 4198000
63 Panacea Biotec Pharma Limited PanEra Biotec Private Limited Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Any other transaction Interest income and Interest Accrued As approved by Board 3153000 2849000 5687000
64 Panacea Biotec Pharma Limited PanEra Biotec Private Limited Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Any other transaction Provision made on Interest earned/accrued As approved by Board 3153000 2849000 5687000
65 Panacea Biotec Pharma Limited PanEra Biotec Private Limited Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Loan As approved by Board 300000 70163000 70463000
66 Panacea Biotec Pharma Limited PanEra Biotec Private Limited Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Any other transaction Provision made on loan given As approved by Board 300000 70163000 70463000
67 Panacea Biotec Pharma Limited Panacea Biotec Inc. Fellow subsidiary Investment As approved by Board 85492000 0 85492000
68 Panacea Biotec Pharma Limited Adveta Power Private Limited Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence Interest received As approved by Board 0 0 0
69 Panacea Biotec Pharma Limited Panacea Biotec Germany Gmbh Fellow subsidiary Any other transaction Reimbursement of expenses As approved by Board 8568000 0 8568000
70 Panacea Biotec Limited Dr. Rajesh Jain Chairman and Managing Director Any other transaction Post Employment Benefits As approved by Nomination and Remuneration Committee and Board 0 0 20789000
71 Panacea Biotec Limited Mr. Ashwani Jain Chief Operating Officer Any other transaction Post Employment Benefits As approved by Nomination and Remuneration Committee and Board 0 0 2000000
72 Panacea Biotec Limited Mr. Devender Gupta CFO and Head IT Any other transaction Post Employment Benefits As approved by Nomination and Remuneration Committee and Board 0 0 1788000
73 Panacea Biotec Limited Mr. Harshet Jain Whole-time Director Any other transaction Post Employment Benefits As approved by Nomination and Remuneration Committee and Board 0 0 563000
74 Panacea Biotec Pharma Limited Mr. Taric Jain Sr. Software Engineer Any other transaction Post Employment Benefits As approved by Nomination and Remuneration Committee and Board 0 0 28000
75 Panacea Biotec Pharma Limited Mr. Ankesh Jain Whole-time Director Any other transaction Post Employment Benefits As approved by Nomination and Remuneration Committee and Board 0 0 1383000
76 Panacea Biotec Limited Mr. Sandeep Jain Joint Managing Director Any other transaction Post Employment Benefits As approved by Nomination and Remuneration Committee and Board 0 0 20463000
77 Panacea Biotec Limited Mr. Tanish Jain Sr. Manager - Global Sourcing Any other transaction Post Employment Benefits As approved by Nomination and Remuneration Committee and Board 0 0 59000
78 Panacea Biotec Limited Mr. Vinod Goel Group CFO and Head Legal & CS Any other transaction Post Employment Benefits As approved by Nomination and Remuneration Committee and Board 0 0 2000000
Total value of transaction during the reporting period 1149090000